Intellia Therapeutics, Inc.NTLANASDAQ
Loading
Year-over-year earnings per share growth rate
3Y CAGR
+16.3%/yr
vs -19.3%/yr prior
Acceleration
+35.6pp
Accelerating
Percentile
P69
Within normal range
vs 3Y Ago
1.6x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 9.78% |
| Q3 2025 | 6.12% |
| Q2 2025 | 10.91% |
| Q1 2025 | 13.39% |
| Q4 2024 | 5.22% |
| Q3 2024 | 11.84% |
| Q2 2024 | -35.71% |
| Q1 2024 | 23.29% |
| Q4 2023 | -5.80% |
| Q3 2023 | 1.60% |
| Q2 2023 | -19.87% |
| Q1 2023 | 16.20% |
| Q4 2022 | 6.23% |
| Q3 2022 | -12.13% |
| Q2 2022 | 32.42% |
| Q1 2022 | -80.01% |
| Q4 2021 | -12.53% |
| Q3 2021 | 3.96% |
| Q2 2021 | -46.38% |
| Q1 2021 | 0.00% |
| Q4 2020 | -46.81% |
| Q3 2020 | 22.95% |
| Q2 2020 | 3.17% |
| Q1 2020 | -10.53% |
| Q4 2019 | -16.33% |
| Q3 2019 | 12.50% |
| Q2 2019 | -14.29% |
| Q1 2019 | -13.95% |
| Q4 2018 | 18.87% |
| Q3 2018 | -1.92% |
| Q2 2018 | -1.96% |
| Q1 2018 | 16.39% |
| Q4 2017 | -38.64% |
| Q3 2017 | 2.22% |
| Q2 2017 | -25.00% |
| Q1 2017 | -16.13% |
| Q4 2016 | -40.91% |
| Q3 2016 | 38.89% |
| Q2 2016 | -80.00% |
| Q1 2016 | 33.33% |